权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

Decision support system for recommending EGFR-inhibiting drugs

推荐EGFR抑制药物的决策支持系统

基本信息

批准号：
10010293
负责人：
金额：
$ 23.88万
依托单位：
PRECIOUS MD LTD
依托单位国家：
英国
项目类别：
Feasibility Studies
财政年份：
2021
资助国家：
英国
起止时间：
2021 至无数据
项目状态：
已结题

来源：
https://gtr.ukri.org/projects?ref=10010293
关键词：
Decision support system recommending EGFR

项目摘要

More than one in three of us will get cancer in our lifetimes. Lung cancer is one of the most common and serious types of cancer. Around 46,500 people are diagnosed with the condition every year in the UK. Better prevention, earlier diagnosis and innovative new treatments mean we have a realistic opportunity to make major improvements in survival. Precious MD works on game-changing and disruptive technologies for detection of the patients who are eligible for receiving targeted therapy. Current approaches are based on invasive and expensive assays on samples taken from biopsy. This can be significantly improved by advanced computation analysisPreciousMD technology merge artificial intelligence capabilities with medical imaging to formulate diagnostic approach beyond what human experts can provide. Due to the high mortality rate and massive public cost burden of lung cancer, Precious MD has focused on this type of cancer at the starting point. Precious MD team is consist of a high profile data scientists, image processing specialists, radiologists, clinical trial, artificial intelligence professionals, specialists and commercial/business management experts from University of Manchester, Oxford and Cambridge. We intend for Precious MD technology to become a routine part of clinical practice and drug development and substantially improve the way of addressing cancer.

我们中超过三分之一的人在一生中会患上癌症。肺癌是最常见和最严重的癌症类型之一。在英国，每年约有46，500人被诊断出患有这种疾病。更好的预防、更早的诊断和创新的新治疗方法意味着我们有现实的机会在生存方面取得重大进展。Precious MD致力于改变游戏规则和颠覆性技术，以检测有资格接受靶向治疗的患者。目前的方法是基于对取自活检的样品的侵入性和昂贵的测定。PreciousMD技术将人工智能功能与医学成像相结合，制定出超越人类专家所能提供的诊断方法。由于肺癌的高死亡率和巨大的公共成本负担，Precious MD从一开始就专注于这类癌症。Precious MD团队由来自曼彻斯特大学、牛津大学和剑桥大学的知名数据科学家、图像处理专家、放射科医生、临床试验、人工智能专业人员、专家和商业/业务管理专家组成。我们希望Precious MD技术成为临床实践和药物开发的常规部分，并大大改善解决癌症的方法。